View Item 

Show simple item record

Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8‐10) prostate cancer treated primarily by radical prostatectomy
dc.contributor.authorWilkins, Lamont J.
dc.contributor.authorTosoian, Jeffrey J.
dc.contributor.authorReichard, Chad A.
dc.contributor.authorSundi, Debasish
dc.contributor.authorRanasinghe, Weranja
dc.contributor.authorAlam, Ridwan
dc.contributor.authorSchwen, Zeyad
dc.contributor.authorReddy, Chandana
dc.contributor.authorAllaf, Mohammed
dc.contributor.authorDavis, John W.
dc.contributor.authorChapin, Brian F.
dc.contributor.authorRoss, Ashley E.
dc.contributor.authorKlein, Eric A.
dc.contributor.authorNyame, Yaw A.
dc.date.accessioned2021-05-12T17:24:04Z
dc.date.available2022-06-12 13:24:03en
dc.date.available2021-05-12T17:24:04Z
dc.date.issued2021-05-01
dc.identifier.citationWilkins, Lamont J.; Tosoian, Jeffrey J.; Reichard, Chad A.; Sundi, Debasish; Ranasinghe, Weranja; Alam, Ridwan; Schwen, Zeyad; Reddy, Chandana; Allaf, Mohammed; Davis, John W.; Chapin, Brian F.; Ross, Ashley E.; Klein, Eric A.; Nyame, Yaw A. (2021). "Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8‐10) prostate cancer treated primarily by radical prostatectomy." Cancer (9): 1425-1431.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/167476
dc.publisherWiley Periodicals, Inc.
dc.subject.otherBlack
dc.subject.otherhigh grade
dc.subject.otherprostatectomy
dc.subject.otherprostate cancer
dc.subject.otherhigh risk
dc.subject.otherAfrican American
dc.titleOncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8‐10) prostate cancer treated primarily by radical prostatectomy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167476/1/cncr33419_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167476/2/cncr33419.pdf
dc.identifier.doi10.1002/cncr.33419
dc.identifier.sourceCancer
dc.identifier.citedreferenceNielsen ME, Han M, Mangold L, et al. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006; 176: 515 ‐ 519.
dc.identifier.citedreferenceSundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in Black American men. J Urol. 2014; 191: 60 ‐ 67.
dc.identifier.citedreferenceMahal BA, Berman RA, Taplin ME, Huang FW. Prostate cancer–specific mortality across Gleason scores in Black vs Nonblack men. JAMA. 2018; 320: 2479 ‐ 2481.
dc.identifier.citedreferenceOptenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long‐term survival from prostate cancer in an equal‐access medical care delivery system. JAMA. 1995; 274: 1599 ‐ 1605.
dc.identifier.citedreferenceDess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer‐specific and other‐cause mortality. JAMA Oncol. 2019; 5: 975 ‐ 983.
dc.identifier.citedreferenceGray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur Urol. 2017; 71: 729 ‐ 737.
dc.identifier.citedreferenceMahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low‐risk prostate cancer and management trends across risk groups in the United States, 2010‐2015. JAMA. 2019; 321: 704 ‐ 706.
dc.identifier.citedreferenceEpstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005; 29: 1228 ‐ 1242.
dc.identifier.citedreferenceSundi D, Tosoian JJ, Nyame YA, et al. Outcomes of very high‐risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer. 2019; 125: 391 ‐ 397.
dc.identifier.citedreferenceMohler JL, Antonarakis ES, Armstrong AJ, et al. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2019; 17: 479 ‐ 505. https://doi.org/10.6004/jnccn.2019.0023
dc.identifier.citedreferencevon Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61: 344 ‐ 349.
dc.identifier.citedreferenceYamoah K, Johnson MH, Choeurng V, et al. Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer. J Clin Oncol. 2015; 33: 2789 ‐ 2796.
dc.identifier.citedreferencePowell IJ, Dyson G, Land S, et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev. 2013; 22: 891 ‐ 897.
dc.identifier.citedreferenceKhani F, Mosquera JM, Park K, et al. Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res. 2014; 20: 4925 ‐ 4934.
dc.identifier.citedreferenceFaisal FA, Sundi D, Tosoian JJ, et al. Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location. Eur Urol. 2016; 70: 14 ‐ 17.
dc.identifier.citedreferenceFaisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post‐prostatectomy. Prostate Cancer Prostatic Dis. 2019; 22: 552 ‐ 559.
dc.identifier.citedreferenceMoses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy. BMC Urol. 2014; 14: 98.
dc.identifier.citedreferenceSchreiber D, Levy EB, Schwartz D, et al. Impact of race in a predominantly African‐American population of patients with low/intermediate risk prostate cancer undergoing radical prostatectomy within an equal access care institution. Int Urol Nephrol. 2014; 46: 1941 ‐ 1946.
dc.identifier.citedreferenceTyson MD, Castle EP. Racial disparities in survival for patients with clinically localized prostate cancer adjusted for treatment effects. Mayo Clin Proc. 2014; 89: 300 ‐ 307.
dc.identifier.citedreferenceAmini E, Palmer TC, Cai J, Lieskovsky G, Daneshmand S, Djaladat H. Association between race and oncologic outcome following radical prostatectomy for clinically organ‐confined prostate cancer: a long‐term follow‐up study. World J Urol. 2018; 36: 1233 ‐ 1239.
dc.identifier.citedreferenceTewari A, Horninger W, Badani KK, et al. Racial differences in serum prostate‐specific antigen (PSA) doubling time, histopathological variables and long‐term PSA recurrence between African‐American and White American men undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2005; 96: 29 ‐ 33.
dc.identifier.citedreferenceCross CK, Shultz D, Malkowicz SB, et al. Impact of race on prostate‐specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J Clin Oncol. 2002; 20: 2863 ‐ 2868.
dc.identifier.citedreferenceEverist MM, Howard LE, Aronson WJ, et al. Socioeconomic status, race, and long‐term outcomes after radical prostatectomy in an equal access health system: results from the SEARCH database. Urol Oncol. 2019; 37: 289.e11 ‐ 289.e17.
dc.identifier.citedreferenceMaurice MJ, Sundi D, Schaeffer EM, Abouassaly R. Risk of pathological upgrading and up staging among men with low risk prostate cancer varies by race: results from the National Cancer Database. J Urol. 2017; 197 ( 3 pt 1 ): 627 ‐ 631.
dc.identifier.citedreferenceYamoah K, Walker A, Spangler E, et al. African‐American race is a predictor of seminal vesicle invasion after radical prostatectomy. Clin Genitourin Cancer. 2015; 13: e65 ‐ e72.
dc.identifier.citedreferencePettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ. Prostate specific antigen and pathological features of prostate cancer in Black and White patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998; 160: 437 ‐ 442.
dc.identifier.citedreferenceHoffman RM, Harlan LC, Klabunde CN, Stephenson RA, Hunt WC, Potosky AL. Racial differences in initial treatment for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Gen Intern Med. 2003; 18: 845 ‐ 853.
dc.identifier.citedreferenceWeiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE. Contemporary management of men with high‐risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017; 20: 283 ‐ 288.
dc.identifier.citedreferenceZeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer. 2003; 98: 496 ‐ 503.
dc.identifier.citedreferenceMoses KA, Paciorek AT, Penson DF, Carroll PR, Master VA. Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol. 2010; 28: 1069 ‐ 1074.
dc.identifier.citedreferenceMoses KA, Orom H, Brasel A, Gaddy J, Underwood W. Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urol Oncol. 2016; 34: 415.e7 ‐ 415.e12.
dc.identifier.citedreferenceMahal BA, Aizer AA, Ziehr DR, et al. Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology. 2014; 84: 386 ‐ 392.
dc.identifier.citedreferenceMahal BA, Chen Y‐W, Muralidhar V, et al. National sociodemographic disparities in the treatment of high‐risk prostate cancer: do academic cancer centers perform better than community cancer centers? Cancer. 2016; 122: 3371 ‐ 3377.
dc.identifier.citedreferenceMahal BA, Ziehr DR, Aizer AA, et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high‐risk prostate cancer. Urol Oncol. 2014; 32: 1285 ‐ 1291.
dc.identifier.citedreferenceZiehr DR, Mahal BA, Aizer AA, et al. Income inequality and treatment of African American men with high‐risk prostate cancer. Urol Oncol. 2015; 33: 18.e7 ‐ 18.e13.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7 ‐ 30.
dc.identifier.citedreferenceChornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate. 2011; 71: 985 ‐ 997.
dc.identifier.citedreferenceMoses KA, Zhao Z, Bi Y, et al. The impact of sociodemographic factors and PSA screening among low‐income Black and White men: data from the Southern Community Cohort Study. Prostate Cancer Prostatic Dis. 2017; 20: 424 ‐ 429.
dc.identifier.citedreferenceFedewa SA, Etzioni R, Flanders WD, Jemal A, Ward EM. Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004‐2006. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2437 ‐ 2444.
dc.identifier.citedreferenceSundi D, Ross AE, Humphreys EB, et al. African American men with very low‐risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013; 31: 2991 ‐ 2997.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33419_am.pdf
Size:
328.3KB
Format:
PDF
View/Open
Name:
cncr33419.pdf
Size:
255.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.